Targeting liver metastasis in uveal melanoma patients may increase survival compared with systemic chemotherapy

Written by Celeste Brady, Commissioning Editor

A new analysis suggests that therapies targeting the liver — the most common site of metastasis in uveal melanoma — increases average survival by a year. The study on the effectiveness of targeted treatment comes after decades of varying treatments with poor overall survival. Researchers at the Sidney Kimmel Cancer Centre at Thomas Jefferson University (PA, USA) have compared survival rates of patients undergoing treatment for uveal melanoma with liver metastasis and found that treatment with liver-targeted therapy increases overall survival following metastasis by 12.5 months, compared with systemic chemotherapy alone. While the researchers have previously reviewed clinical factors predictive...

To view the full article, please register now for access

It's completely free